ArticleFrontiers in nutrition2025
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protective effects of polysaccharide SH-P-1-1 isolated fromFrontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperuricemia (HUA) is the presence of excessive uric acid (UA) in blood, which leads to an increased risk of chronic kidney disease and gout. There are about 120 million hyperuricemia patients in China, which has surpassed diabetes as the second largest chronic disease. Objective: The aim of the present study was to investigate the hypouricemic effects of Methods: This study established a mouse HUA model by gavage of potassium oxonate (PIO) and hypoxanthine (HX), and treated with DH to investigate the therapeutic effect of DH on hyperuricemia. Use a biochemical assay kit to detect changes in the levels of UA, creatinine (Cr), and urea nitrogen (BUN) in mouse serum; Use ELISA kit to detect the activity of xanthine oxidase (XOD) in serum; Untargeted Metabolomics analysis was performed on the serum of each group of mice using liquid chromatography-mass spectrometry. This study recruited 23 HUA volunteers, volunteers drank 0.5 g DH daily for four consecutive weeks, with serum UA levels measured once a week. Results: Animal experiments have shown that DH has therapeutic effects on HUA, mainly manifested as: DH effectively reduces the levels of UA, Cr, and BUN in the serum of HUA mice, lowers XOD activity in the serum, and alleviates kidney tissue and glomerular damage. Metabolomics analysis showed that there were 306 significant differences in metabolites between the Sham group, HUA model group, and DH group. Pathway analysis of these differential metabolites revealed that they were mainly involved in pyrimidine metabolism, histidine metabolism, and riboflavin metabolism. Clinical research results show that after drinking DH, UA levels in HUA volunteers significantly decreased, and most HUA volunteers' UA levels decreased to normal levels. Conclusion: DH has the effect of preventing and treating hyperuricemia, and it belongs to the same class of traditional Chinese medicine as medicine and food, with extremely low toxicity and high safety. Therefore, DH is suitable for preparation as a product for preventing and treating HUA in functional food and other products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.